Compass Pathways prices $150M offering of ADS and warrants to fund Phase 3 depression/PTSD trials

COMPASS Pathways plc

Offering of 24.0M ADS and 11.0M pre-funded warrants plus accompanying ADS warrants at $4.275/unit (ADS warrant strike $5.796).
Gross proceeds ~$150M; up to ~$353M if ADS warrants fully exercised; led by Deep Track Capital.
Net proceeds fund ongoing COMP005/COMP006 Phase 3 depression trials (data Q2 2025, H2 2026) and accelerate PTSD program.
Company terminates ATM sales agreement (up to $93.5M capacity) effective January 9, 2025.
Offering expected to close January 13, 2025; 60-day lock-up for officers/directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.